Irritable Bowel Syndrome Mixed
8
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
Efficacy of Chatbot for Irritable Bowel Syndrome (IBS) Patients
GOS to Reduce Symptom Severity in IBS
Faecal Microbiota Transplantation in Irritable Bowel Syndrome
Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome
The Effect of AI-based Microbiome Diet on IBS-M Symptoms
Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome